Mesenchymal Stem Cell Extracellular Vesicles as a New Treatment Paradigm in Solid Abdominal Organ Transplantation: A Case Series
Stem Cells and Development · 2024-03 · 33 (5-6) · 107-116
DOI: 10.1089/scd.2023.0273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells and Development, online erschienen am 04.03.2024. Verfasst von Amy L Lightner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Center for Gut Rehabilitation and Transplantation, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio,…. Hauptthemen laut MEDLINE: Mesenchymal Stem Cell Transplantation, Graft vs Host Disease, Mesenchymal Stem Cells, Extracellular Vesicles. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Solid abdominal organ transplantation is fraught with variable rates of rejection and graft versus host disease (GVHD). We sought to determine the safety and efficacy of an advanced extracellular vesicle (EV) investigational product (IP) derived from mesenchymal stem cells (MSC) in the transplant patient population. Seven separate emergency investigational new drug (eNIDs) were filed with the Food and Drug Administration (FDA) for the emergency treatment of rejection of an isolated intestinal graft ( n = 2), liver allograft graft ( n = 2), modified multivisceral graft ( n = 3), and GVHD in isolated intestinal transplant patients ( n = 2). Fifteen milliliters of IP was administered intravenously on Day 0, 2, 4, and this treatment cycle was repeated up to four times in each patient depending on the treatment protocol allowed by the FDA. Safety (adverse event reporting) and efficacy (clinical status, serologies, and histopathology) were evaluated. There were no adverse events related to IP. All patients had improvement in clinical symptoms within 24 h, improved serologic laboratory evaluation, improved pulmonary symptoms and dermatologic manifestations of GVHD, and complete histologic resolution of graft inflammation/rejection within 7 days of IP administration. Systemic use of a MSC-derived EV IP was successful in achieving histological clearance of intestinal, liver, and multivisceral graft inflammation, and skin and pulmonary manifestations of GVHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Colorectal Surgery, Center for Gut Rehabilitation and Transplantation, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio, USA.
- Department of Abdominal Transplantation, Center for Gut Rehabilitation and Transplantation, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio, USA.
- Department of General Surgery, Center for Gut Rehabilitation and Transplantation, Digestive Disease and Surgery Institute, Cleveland Clinic, Ohio, USA.
- Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Ohio, USA.
ORCID-Profile: Amy L Lightner
Zitieren
APA
Lightner, A. L., Fujiki, M., Elshawy, M., Dadgar, N., Barnoski, A., Osman, M., Fulmer, C. G., & Vaidya, A. (2024). Mesenchymal Stem Cell Extracellular Vesicles as a New Treatment Paradigm in Solid Abdominal Organ Transplantation: A Case Series. Stem Cells and Development, 33(5-6), 107-116. https://doi.org/10.1089/scd.2023.0273
Vancouver
Lightner AL, Fujiki M, Elshawy M, Dadgar N, Barnoski A, Osman M, et al. Mesenchymal Stem Cell Extracellular Vesicles as a New Treatment Paradigm in Solid Abdominal Organ Transplantation: A Case Series. Stem Cells and Development. 2024;33(5-6):107-116. doi:10.1089/scd.2023.0273
BibTeX
@article{Lightner2024,
author = {Lightner, Amy L and Fujiki, Masato and Elshawy, Mohamed and Dadgar, Neda and Barnoski, Anita and Osman, Mohammed and Fulmer, Clifton G and Vaidya, Anil},
title = {Mesenchymal Stem Cell Extracellular Vesicles as a New Treatment Paradigm in Solid Abdominal Organ Transplantation: A Case Series},
journal = {Stem Cells and Development},
year = {2024},
volume = {33},
number = {5-6},
pages = {107--116},
doi = {10.1089/scd.2023.0273}
}
EUVIMED